Illumina, Inc. (NASDAQ:ILMN) has been given a consensus recommendation of “Buy” by the seventeen brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $346.35.
ILMN has been the subject of several recent analyst reports. ValuEngine cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $347.00 target price for the company in a research note on Friday, January 11th. Bank of America restated a “buy” rating and issued a $355.00 target price on shares of Illumina in a research note on Wednesday, January 30th. Barclays raised their target price on shares of Illumina from $350.00 to $370.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 24th. Finally, Deutsche Bank cut shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price for the company. in a research note on Friday, January 25th.
Shares of ILMN stock traded up $2.67 during mid-day trading on Wednesday, hitting $284.54. The stock had a trading volume of 23,002 shares, compared to its average volume of 1,080,291. Illumina has a fifty-two week low of $207.51 and a fifty-two week high of $372.61. The stock has a market capitalization of $41.31 billion, a PE ratio of 49.70, a price-to-earnings-growth ratio of 2.00 and a beta of 1.20. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46.
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, January 29th. The life sciences company reported $1.32 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.04). Illumina had a return on equity of 25.44% and a net margin of 24.79%. The firm had revenue of $867.00 million during the quarter, compared to analyst estimates of $865.33 million. During the same quarter last year, the business posted $1.44 EPS. The firm’s revenue was up 11.4% on a year-over-year basis. Equities analysts forecast that Illumina will post 6.53 earnings per share for the current fiscal year.
In related news, SVP Charles Dadswell sold 124 shares of the firm’s stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $294.71, for a total value of $36,544.04. Following the completion of the sale, the senior vice president now owns 7,003 shares in the company, valued at $2,063,854.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction dated Monday, November 12th. The shares were sold at an average price of $314.63, for a total transaction of $3,146,300.00. Following the completion of the sale, the senior vice president now owns 79,612 shares of the company’s stock, valued at approximately $25,048,323.56. The disclosure for this sale can be found here. Insiders sold 49,247 shares of company stock valued at $15,204,166 in the last quarter. Company insiders own 0.54% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in ILMN. Moody National Bank Trust Division acquired a new position in Illumina during the fourth quarter worth about $31,000. Virtus ETF Advisers LLC acquired a new position in Illumina during the fourth quarter worth about $31,000. Oregon Public Employees Retirement Fund raised its position in Illumina by 66,581.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after acquiring an additional 10,546,495 shares during the last quarter. Arcadia Investment Management Corp MI acquired a new position in Illumina during the fourth quarter worth about $39,000. Finally, Exane Derivatives raised its position in Illumina by 12,900.0% during the fourth quarter. Exane Derivatives now owns 130 shares of the life sciences company’s stock worth $39,000 after acquiring an additional 129 shares during the last quarter. Institutional investors own 88.94% of the company’s stock.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Read More: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.